FDA has accepted a license for complementary biological products from Mercadon Gardasil 9
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the U.SPharmaceutical sandannounced that the U.SFood andDrug(
FDA) has accepted a supplementary biologics license (sBLA) for the Gardasil 9 (Plus, 9-price recombinant human papillomavirus vaccine) and granted priority review eligibility, its prescription drug user charge spending law (PDUFA) date of October 6, 2018the sBLA aims to seek approval to expand Gardasil 9's age-adaptation for men and women aged 27-45 to prevent certain cancers and diseases caused by the nine hpv types covered by the vaccineabout Gardasil 9the most common type of HPV in the world than any listed HPV vaccine, which, after type 16 and 18 HPV, is the most common type of HPV caused worldwidein the United States, Gardasil 9 is suitable for women aged 9-26 to prevent 7 types of high-risk HPV (16, 18, 31, 33, 45, 52, 58) caused by cervical, vulva, vaginal, cancer, and prevent syltosis caused by 2 types of low-risk HPV (6, 11)in addition,, Gardasil 9 is also suitable for men aged 9-26 to prevent 7 types of high-risk HPV (16, 18, 31, 33, 45, 52, 58) caused by cancer, prevention of genital warts caused by 2 low-risk HPV (6, 11), prevention of 9 types of HPV (6, 11, 16, 18, 31, 33, 45, 52, 58) or pre-cancerous diseaseto date, Gardasil 9 has been approved for use in more than 70 countries around the world
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
